Spots Global Cancer Trial Database for gemcitabine 1000 mg
Every month we try and update this database with for gemcitabine 1000 mg cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer | NCT05026905 | Phase II, Open-... | Gemcitabine 100... Nab paclitaxel S1 leucovorin Oxaliplatin | 20 Years - | National Health Research Institutes, Taiwan | |
| Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy | NCT03422523 | Diffuse Large B... Relapsed Diffus... Refractory Diff... | Atezolizumab Rituximab Gemcitabine 100... Oxaliplatin 100... | 16 Years - | University Hospital Southampton NHS Foundation Trust | |
| Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients | NCT05821556 | Adenocarcinoma ... | Valproic acid Simvastatin 20m... Gemcitabine 100... Nab paclitaxel Cisplatin Capecitabine | 18 Years - | National Cancer Institute, Naples | |
| Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy | NCT03422523 | Diffuse Large B... Relapsed Diffus... Refractory Diff... | Atezolizumab Rituximab Gemcitabine 100... Oxaliplatin 100... | 16 Years - | University Hospital Southampton NHS Foundation Trust | |
| Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL | NCT03259529 | Diffuse Large B... | Bendamustine hy... Gemcitabine 500... Gemcitabine 700... Gemcitabine 100... Nivolumab Rituximab | 18 Years - 70 Years | St. Petersburg State Pavlov Medical University | |
| Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer | NCT03492671 | Pancreas Adenoc... Resectable Panc... | Gemcitabine 100... nab-paclitaxel Stereotactic Bo... | 18 Years - | Loma Linda University | |
| Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL | NCT03259529 | Diffuse Large B... | Bendamustine hy... Gemcitabine 500... Gemcitabine 700... Gemcitabine 100... Nivolumab Rituximab | 18 Years - 70 Years | St. Petersburg State Pavlov Medical University | |
| Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL | NCT03259529 | Diffuse Large B... | Bendamustine hy... Gemcitabine 500... Gemcitabine 700... Gemcitabine 100... Nivolumab Rituximab | 18 Years - 70 Years | St. Petersburg State Pavlov Medical University | |
| Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer | NCT03492671 | Pancreas Adenoc... Resectable Panc... | Gemcitabine 100... nab-paclitaxel Stereotactic Bo... | 18 Years - | Loma Linda University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
